FDA advisers unanimously agree Reata's kidney drug is not effective at slowing disease progression Novartis works on pan-coronavirus pill, eyes 2022 human testing Science, talent, money: Eir raises $138M VC fund to fill gap in Nordic life science scene Totus tots up $40M in series A funding to go after competitive cancer space K36 emerges with $30M to bankroll multiple myeloma drug in-licensed from Novartis AstraZeneca's Evusheld becomes first FDA-authorized COVID antibody to protect the immunocompromised before exposure City of Hope to acquire Cancer Treatment Centers of America for a reported $390M Philips clinches FDA clearance for patient monitors that garnered emergency OK amid pandemic ASH: Senti Bio's gene circuit CAR-NK cell therapy enhances cancer killing and safety in leukemia models Featured Story | By Kyle LaHucik A panel of FDA advisers said Reata Pharmaceuticals' main drug, bardoxolone, did not prove effective at slowing the progression of chronic kidney disease in Alport syndrome. The FDA is scheduled to decide whether to approve the med, for a rare genetic condition called Alport syndrome, in February 2022. read more |
| |
|---|
|
Top Stories By Ben Adams Unlike some of its Big Pharma peers, Novartis has not been at the forefront of creating new vaccines and treatments against COVID. Now, however, it’s taking its massive R&D budget and targeting not just the current pandemic, but all coronaviruses. read more By Nick Paul Taylor The Nordic life sciences scene is getting an injection of cash. Led by centers such as the Karolinska Institutet and Copenhagen University, the region leads the way in research in the EU by many metrics but has traditionally lacked the vibrant VC scene needed to build large numbers of biotechs. Eir Ventures wants to help change that. read more By Nick Paul Taylor Totus Medicines is making a play for the PI3Kα inhibitor market. Exiting stealth with a $40 million series A round, the Massachusetts-based biotech plans to advance a molecule designed to improve on existing PI3Kα inhibitors such as Novartis’ Piqray. read more By Kyle LaHucik K36 Therapeutics launched with $30 million to bankroll the clinical entry of a multiple myeloma small-molecule in-licensed from Novartis. The oral drug targets a subset of the plasma cell cancer that is found in about 20% of patients and the biotech expects to begin testing it next year. read more By Kevin Dunleavy People in the U.S. with conditions that prevent them from building immunity with COVID-19 vaccines will soon have a way to get adequate protection from the virus, as the FDA has approved AstraZeneca’s long-acting antibody cocktail Evusheld. read more By Anastassia Gliadkovskaya The transaction will expand City of Hope’s portfolio and contribute not only to its cancer services but also to research and development. read more By Andrea Park Over a year after doling out an emergency use authorization for a handful of Philips’ IntelliVue patient monitoring devices, the FDA is doubling down on the regulatory nod. read more By Angus Liu Selecting the right target to kill off cancer cells while sparing healthy cells has been challenging for companies developing off-the-shelf cell therapies. Now, Senti Bio has promising early data on its CAR-NK therapy, developed from the biotech’s gene circuit platform, in acute myeloid leukemia. read more Resources Sponsored by: WIRB - Copernicus Group Sites receiving augmentation support enroll more than 30,000 patients in just over three months. See how additional site resources can make a difference. Sponsored By: BBK Worldwide Create more inclusive clinical trials, enroll them faster, and keep participants engaged longer with the latest Study Voices survey results and insights. Sponsored by: GLG A major Korean biopharmaceutical company wanted to gather unbiased opinions on a new cancer treatment product. Fill out our form to learn more. Sponsored by: GLG Download now to learn how GLG helped a biotech company plan for the demand of a new drug/device combination by commissioning a forecasting study. Sponsored by: Thermo Fisher Scientific A variety of genetic analysis methods are valuable in ensuring that ex vivo human cells to be used for cell-based therapies are correctly identified, have the correct characteristics, and are free of contaminants. Sponsored by: Thermo Fisher Scientific Learn how a CDMO partnered with Thermo Fisher Scientific to manage high-volume process liquid and buffer preparation scale-up. Download the free case study from Thermo Fisher Scientific Sponsored by: Clario This whitepaper addresses where AI can make the biggest impact in clinical trials. The stakes are too high for patients to leave decision-making to machines, but AI can lend administrative support that empowers staff and medical experts alike to carry out their jobs more effectively. Sponsored by: TransPerfect Life Sciences If you’re thinking about leveraging the benefits of increased quality, reduced costs, and shortened turnaround times that machine translation (MT) has to offer, check out this quick guide for the top 10 considerations when implementing MT. Sponsored by: Medable, Inc. Find out how to improve clinical protocol adherence, and thus patient outcomes, by 15%+ with Medable’s latest White Paper. Sponsored by: IQVIA Learn how to elevate your omnichannel marketing strategy with Next Best - a combination of data and analytics, deployed to facilitate decision making. Sponsored by: Catalent Biologics Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Informa Pharma Intelligence and Oracle Health Sciences New market research provides valuable insight into the impact of adaptations made in clinical trials during the pandemic. Sponsored by: Thermo Fisher Scientific Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. Fierce Virtual Clinical Trials Summit December 6-7, 2021 | Philadelphia, PA Fierce JPM Week 2022 January 11, 2022 | San Francisco, CA
January 18-20, 2022 | Virtual Event Fierce Drug Safety Summit February 8-9, 2022 | Arlington, VA Fierce BD&L Summit March 2022 | San Francisco, CA Fierce Promotional Review Committee Compliance and Best Practices Summit April 12-14, 2022 | New Brunswick, NJ Fierce Medical Affairs Strategic Summit (MASS) East April 12-14, 2022 | New Brunswick, NJ Fierce Health IT Summit April 20, 2022 | Virtual Event Fierce Trial Master File Summit May 2022 | Location TBD Fierce Digital Pharma Innovation Week June 2022 | Virtual Event Fierce Biotech Next-Gen June 29, 2022 | Virtual Event Fierce Pharma PR & Communications Summit July 2022 | Location TBD (NYC Metro Area) Fierce Biotech Forum October 2022 | Location TBD Fierce Biotech Virtual Forum October 19, 2022 | Virtual Event | 